Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection
- PMID: 17389912
- PMCID: PMC1824710
- DOI: 10.1371/journal.pone.0000321
Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection
Abstract
Background: CD8+ T cells impact control of viral infections by direct elimination of infected cells and secretion of a number of soluble factors. In HIV-1 infection, persistent HIV-1 specific IFN-gamma+ CD8+ T cell responses are detected in the setting of disease progression, consistent with functional impairment in vivo. Recent data suggest that impaired maturation, as defined by the lineage markers CD45RA and CCR7, may contribute to a lack of immune control by these responses.
Methodology/principal findings: We investigated the maturation phenotype of epitope-specific CD8+ T cell responses directed against HIV-1 in 42 chronically infected, untreated individuals, 22 of whom were "Controllers" (median 1140 RNA copies/ml plasma, range<50 to 2520), and 20 "progressors" of whom had advanced disease and high viral loads (median 135,500 RNA copies/ml plasma, range 12100 to >750000). Evaluation of a mean of 5 epitopes per person revealed that terminally differentiated CD8+ T cells directed against HIV-1 are more often seen in HIV-1 Controllers (16/22; 73%) compared to HIV-1 progressors (7/20; 35%)(p = 0.015), but the maturation state of epitope-specific responses within a given individual was quite variable. Maturation phenotype was independent of the HLA restriction or the specificity of a given CD8+ T cell response and individual epitopes associated with slow disease progression were not more likely to be terminally differentiated.
Conclusions/significance: These data indicate that although full maturation of epitope-specific CD8+ T cell responses is associated with viral control, the maturation status of HIV-1 specific CD8+ T cell responses within a given individual are quite heterogeneous, suggesting epitope-specific influences on CD8+ T cell function.
Conflict of interest statement
Figures




Similar articles
-
HIV replication leads to skewed maturation of CD8-positive T-cell responses in infected children.New Microbiol. 2010 Oct;33(4):303-9. New Microbiol. 2010. PMID: 21213588
-
Characterization of virus-specific CD8(+) effector T cells in the course of HIV-1 infection: longitudinal analyses in slow and rapid progressors.Clin Immunol. 2004 Dec;113(3):299-309. doi: 10.1016/j.clim.2004.08.002. Clin Immunol. 2004. PMID: 15507395
-
Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.J Virol. 2005 Nov;79(22):14169-78. doi: 10.1128/JVI.79.22.14169-14178.2005. J Virol. 2005. PMID: 16254352 Free PMC article.
-
Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue.Trends Immunol. 2002 Dec;23(12):586-91. doi: 10.1016/s1471-4906(02)02326-8. Trends Immunol. 2002. PMID: 12464570 Review.
-
Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection.Blood. 2001 Sep 15;98(6):1667-77. doi: 10.1182/blood.v98.6.1667. Blood. 2001. PMID: 11535496 Review.
Cited by
-
Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells.Clin Vaccine Immunol. 2009 Oct;16(10):1504-16. doi: 10.1128/CVI.00104-09. Epub 2009 Aug 19. Clin Vaccine Immunol. 2009. PMID: 19692626 Free PMC article.
-
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.AIDS Res Ther. 2008 Oct 6;5:22. doi: 10.1186/1742-6405-5-22. AIDS Res Ther. 2008. PMID: 18837993 Free PMC article.
-
Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations.J Immunol. 2014 Dec 1;193(11):5626-36. doi: 10.4049/jimmunol.1401017. Epub 2014 Oct 27. J Immunol. 2014. PMID: 25348625 Free PMC article.
-
The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells.JCI Insight. 2023 Sep 22;8(18):e169028. doi: 10.1172/jci.insight.169028. JCI Insight. 2023. PMID: 37581929 Free PMC article.
-
HIV-1 Vaccine Trials: Evolving Concepts and Designs.Open AIDS J. 2012;6:274-88. doi: 10.2174/1874613601206010274. Epub 2012 Nov 30. Open AIDS J. 2012. PMID: 23289052 Free PMC article.
References
-
- Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9:861–866. - PubMed
-
- Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol. 2004;4:630–640. - PubMed
-
- Draenert R, Goebel FD. What's new in HIV/AIDS. Protective immunity in HIV infection: where do we stand? Infection. 2004;32:250–252. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials